Decent end to 2025, but suspicions rise over future execution abilities
27/02/26 -"The Q4 results were ahead of consensus, but a lack of 2026 sales guidance casts doubt over Grifols’ ability to deliver on its 2029 sales and profitability outlook (announced in February 2025). ..."
Pages
50
Language
English
Published on
27/02/26
You may also be interested by these reports :
06/03/26
We have incorporated the 2025 reported figures and added a new forecast year (2028) to our model. Consequently, we have reduced the out-year sales ...
05/03/26
The Q4 results fell somewhat short of expectations, as Life Science and Healthcare witnessed decent growth, whereas the quarter was tough for ...
05/03/26
Who would have believed that amongst the star-studded European pharma names, the tiny (in market cap terms, relative to Big Pharmas) Faes Farma (ADD; ...
04/03/26
The Q4 results exceeded expectations, with Crop Science being a key top-line driver. Adjusted EBITDA declined for all three divisions. While the 2026 ...